U14 Syngeneic Model Service for Cervical Cancer

The U14 syngeneic model of cervical cancer propagates a chemically induced murine cervical squamous carcinoma in fully immunocompetent 615 or C57BL/6 hosts, pairing a metastasis-rich phenotype with a six-decade publication heritage. Alfa Cytology delivers the complete U14 workflow—authenticated cell banking, subcutaneous, footpad or intraperitoneal implantation, burden-balanced randomization, scheduled dosing and metastasis-inclusive endpoint analysis—giving sponsors decision-ready preclinical datasets shaped to their program, strictly within a preclinical scope.

Overview of U14 Syngeneic Model for Cervical Cancer

U14 is a genuine artifact of experimental oncology’s carcinogen era: in 1958, researchers at the Chinese Academy of Medical Sciences and Peking Union Medical College applied 20-methylcholanthrene to the uterine cervix of a mouse and, from the tumor that arose, established a transplantable line that has been maintained ever since. Pathology settled its identity in the 1980s as an undifferentiated squamous carcinoma of the cervix, and the classical transplant statistics remain arresting—lymph-node metastasis in 95% of recipients, lung metastasis in 80%, and a mean survival of 27 days—earning U14 its reputation as a bidirectional (lymphatic and hematogenous) metastasis strain. A modern re-establishment and characterization (Gu and colleagues, 2008) described epithelioid cells that grow adherent with partial suspension, stain positive for cytokeratin, divide every ~21.8 hours, and carry a hypotetraploid karyotype of 64–68 chromosomes, with 100% tumorigenicity in both 615 and C57BL/6 mice. The same laboratory produced a fully GFP-positive monoclonal derivative, while parallel work selected organ-preference substrains—the pulmonary line U14AP11 (cell line P11-90) and the lymphatic line U14AL10 (L10-90)—that remain useful for studying metastatic organotropism.

Fig 1. GAS6-AXL axis validation in the U14 orthotopic model: U14 and HeLa migration/invasion under GAS6 stimulation ± Bemcentinib (AXL inhibitor), with normal cervix vs cervical cancer mIHC (AXL⁺pan-CK⁺, GAS6⁺C3⁺COL1A1⁺) and TCGA/GSE prognosis. (Zhan, Jijie, et al., 2026)

As a syngeneic platform, U14 has served immunotherapy research for decades, most notably the B7-1 (CD80)-transfected vaccine studies in 615 mice that demonstrated protective and therapeutic antitumor immunity, and it offers a feature rare among cervical models: HPV16 E6- and E7-transfected derivatives whose altered latency (tumor appearance extending from 5–7 to 8–14 days) and dampened metastasis make them purpose-built substrates for E6/E7-targeted strategies. Practical formats are flexible—subcutaneous flank tumors for efficacy screening, footpad implants that enrich for nodal spread, and intraperitoneal inoculation as low as 1 × 10⁵ cells, which generates trackable ascites within days in fluorescent derivatives. Gefitinib (ZD1839) has been run through this model as an oral dose-response benchmark, confirming its utility for tyrosine-kinase-inhibitor screening. The caveats are specific and manageable: BALB/c is only partially compatible (roughly half of recipients take), the classic 615 strain is maintained by a limited circle of institutions, and the line’s brisk kinetics compress treatment windows—all outweighed, for many programs, by an immunocompetent host with a uniquely well-documented metastatic pedigree.

Cell Line Information: U14

Key characteristics of U14 and its documented derivatives are summarized below.

Our Services

With in vivo oncology specialists guiding each stage and pathology, fluorescence imaging and immune-profiling capabilities in-house, Alfa Cytology adapts every U14 engagement to the sponsor’s hypothesis—selecting the implant site and strain to shape the metastatic question, calibrating dose and schedule to the line’s brisk kinetics, and pairing endpoints with histology, immunohistochemistry and flow cytometry for clean, decision-grade preclinical data.

Workflow of U14 Syngeneic Model Construction

Construction of the U14 syngeneic model is an implantation workflow whose quality rests on verified cells, strain-matched immunocompetent recipients, standardized technique and a disciplined measurement cadence. A standard engagement proceeds as follows:

1. Source and qualify cells: U14 stocks are cleared by mycoplasma PCR and identity verification (cytokeratin-positive epithelial phenotype confirmed); U14-GFP or luciferase labeling is titrated in vitro before expansion where imaging readouts are required.
2. Prepare recipients: 615 or C57BL/6 mice (typically 6–8 weeks old; BALB/c avoided given partial incompatibility) complete acclimation and health screening and are individually marked before implantation.
3. Prepare the inoculum: log-phase cells are harvested, washed, counted and resuspended in PBS (commonly 1 × 10⁷/mL for a 100 µL dose); an intraperitoneal ascites format uses as few as 1 × 10⁵ cells.
4. Implant: 1 × 10⁶ cells are injected subcutaneously into the flank, or into the footpad where lymphatic spread is the readout of interest, with consistent anatomical positioning for reproducible caliper geometry.
5. Randomize: when tumors reach palpability (typically day 5–7 for wild-type cells), animals are assigned to groups balanced by tumor volume and body weight.
6. Dose and follow: test articles are administered on schedule; tumors are measured with calipers two to three times weekly (volume typically 0.52 × length × width²), with fluorescence or bioluminescence substituted for labeled cohorts; body weight and clinical status are logged in parallel, and survival is recorded where the design requires.
7. Terminate and analyze: tumors are resected and weighed; draining lymph nodes, lungs and peritoneal cavity are inspected for metastasis; tissues then enter histopathology, immunohistochemistry, flow-cytometric immune profiling and molecular analysis.

Fig 2. U14 Syngeneic Model construction workflow.

Case Study-U14 Syngeneic Model Development

Alfa Cytology keeps an active file of preclinical case studies on the U14 platform: establishment-phase optimization of strain selection, implant site and dose; in vivo growth tracking by caliper or fluorescence; immunotherapy, HPV-targeted and kinase-inhibitor intervention studies; and systematic lymph-node, pulmonary and peritoneal metastasis quantification with matched immune profiling. Representative growth curves, imaging series and endpoint summaries can be shared upon request and will be updated as new programs conclude.

Why Choose Alfa Cytology?

A model with U14’s metastatic pedigree rewards careful host matching and endpoint discipline, and those are exactly the habits Alfa Cytology brings:

• Strain-matched execution in 615 or C57BL/6 hosts, with documented avoidance of partially incompatible backgrounds.
• Authenticated U14 banks with U14-GFP or luciferase labeling available for imaging-driven designs.
• Site-flexible implantation (flank, footpad, intraperitoneal) that lets the experimental question dictate the metastatic route.
• A six-decade metastasis pedigree—lymph-node and lung spread—quantified with histological confirmation.
• Ready access to documented derivatives, including pulmonary and lymphatic organotropism substrains and HPV16 E6/E7 transfectants.
• Dosing calendars engineered around brisk kinetics so compressed windows still deliver interpretable data.
• One accountable project contact with milestone-by-milestone visibility.
• A strictly preclinical scope—every study is planned, executed and reported as non-clinical research.

Contact Us

Interested in the U14 syngeneic cervical cancer model for your next preclinical program? Reach out to us with your agent, timeline and endpoint wish-list, and the Alfa Cytology team will respond with a customized plan covering model setup, dosing strategy and analysis workflow—contact us today and move your program forward with confidence.

For research use only. Not intended for any clinical use.